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of age, and the attack rate decreased as 
patients’ ages increased (6).
Reactive vaccination campaigns 
in some communes of Madarounfa 
district that had reached the epidemic 
threshold were launched by the Minis-
try of Public Health with a remaining 
2009 stockpile (16,527 doses, 35.7% 
coverage) of the quadrivalent polysac-
charide vaccine (A/C/Y/W135) from 
Médecins sans Frontières. The Interna-
tional Coordinating Group on Vaccine 
Provision for Epidemic Meningitis 
Control has also recently approved the 
release of 381,526 doses of trivalent 
polysaccharide vaccine (A/C/W135) 
for vaccination campaigns in Maradi 
and Zinder districts. Future immuniza-
tion campaigns will be implemented 
by Ministry of Public Health with the 
support of the World Health Organiza-
tion and partners, including Médecins 
sans Frontières and The United Na-
tions Children’s Fund.
Given the large population at 
risk, and the low availability and high 
cost of the trivalent vaccine, a sound 
vaccination strategy is of particular 
importance to mitigate the expansion 
of serogroup W135 in the country. 
Microbiologic surveillance is critical 
in the early and accurate detection of 
meningococcal serogroups for deter-
mining the appropriate vaccine. 
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Toscana Virus 
Infection in 
American Traveler 
Returning from 
Sicily, 2009 
To the Editor: Since the discov-
ery of Toscana virus (TOSV) in 1971 
in Tuscany (1), sandfl y-borne TOSV 
has become recognized as a leading 
cause of acute meningitis in central 
Italy during the summer (2). France, 
Spain, Portugal, Greece, and Cyprus 
have also reported cases of TOSV in-
fection (2). Although TOSV has been 
detected in sandfl ies in Sicily (3), we 
are not aware of any historically docu-
mented human infection with TOSV 
in this southernmost region of Italy.
We report TOSV infection of an 
American male physician, 65 years of 
age, who traveled to Sicily for 3 weeks 
and returned to the United States in 
October 2009. Two days after his re-
turn, he awoke with a headache, and 
hours later he noticed diffi culty fi nd-
ing words. His headache progressed, 
and during the next few hours, he 
experienced severe expressive dys-
phasia. At admission to the hospital, 
he denied having fever, nuchal rigid-
ity, photophobia, nausea, vomiting, or 
diarrhea.
Other than changing planes in Mi-
lan, the patient had remained in Sicily 
during the entire 3 weeks of his visit. 
He had sustained both mosquito and 
what he thought were fl ea bites while 
in Sicily. He had no known exposure 
to bats, rabid animals, or ticks.
Computed tomographic scan and 
magnetic resonance imaging of the 
brain showed no mass lesions or ab-
normality of the cerebral vessels. A 
sample of cerebrospinal fl uid (CSF) 
obtained at admission showed 14 
leukocytes/mm3 (reference range 0–5 
leukocytes/mm3) with 100% lympho-
cytes, a protein level of 126 mg/dL 
(reference range 15–45 mg/dL), and a 
glucose level of 63 mg/dL (reference 
range 50–80 mg/dL). A nasopharyn-
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geal swab specimen was negative for 
infl uenza A and B virus antigens. Oth-
er than a decreased thrombocyte count 
and an elevated serum glucose level, 
the results of complete blood count, 
comprehensive chemical panel, and 
coagulation studies were within nor-
mal limits. PCR results for CSF were 
negative for herpes simplex virus, en-
terovirus, and parechovirus. Test re-
sults for acute-phase and convalescent-
phase serum specimens performed at 
the Washington State Department of 
Health Laboratory were negative for 
West Nile virus and St. Louis enceph-
alitis virus immunoglobulin M. 
Serum and CSF were sent to the 
Centers for Disease Control and Pre-
vention in Fort Collins, Colorado. 
TOSV RNA was detected in a CSF 
sample collected on day 1 of illness by 
using reverse transcription–PCR (4). 
Plaque-reduction neutralization assays 
demonstrated a >4-fold rise in TOSV 
neutralizing antibodies between paired 
serum specimens collected on days 
1 (titer <1:10) and 21 (titer 1:320) of 
illness. No similar rise in neutralizing 
antibodies to serologically related phle-
boviruses (e.g., sandfl y fever Naples 
virus and sandfl y fever Sicilian virus) 
was detected. The patient received sup-
portive care only. He had a complete 
neurologic recovery in 10 days and was 
able to return to work.
Phylogenetic analyses indicate that 
2 geographically distinct genotypes, 
the Italian and Spanish lineages of 
TOSV, circulate throughout the Medi-
terranean region (5). To determine the 
lineage of the infecting strain, we per-
formed advanced molecular analyses 
of TOSV RNA isolated from the in-
fected traveler’s CSF. These analyses 
used published consensus primers that 
target the small (S) segment (4) as well 
as primers newly designed to target 
the medium (M) segment: M 851F, 5′-
ACCAAATACAACCATAGCCCC-3′ 
(forward) and M 1327c, 5′-ATA
CAATTCCCACAGTCGTTAG-3 ′ 
(reverse) of the multisegment TOSV 
genome. Reverse transcription–PCR 
amplifi cation and nucleotide sequenc-
ing generated 2 nt sequences of 332 (S 
segment) and 424 (M segment) nucle-
otides in length. Phylogenetic analy-
ses of the newly determined sequences 
and sequences previously determined 
for Mediterranean TOSV isolates of 
diverse origin were carried out by us-
ing MEGA version 4 (6). According 
to phylogenetic inference, the TOSV 
RNA identifi ed in the returning traveler 
is of the Italian lineage (Figure). Of in-
terest, the TOSV M segment sequence 
generated from this patient aggregates 
with extreme bootstrap support along 
with that generated previously from a 
strain of TOSV that was isolated from 
sand fl ies in Palermo, Sicily, in 1993 
(Figure), indicating that the infect-
ing strain is likely representative of 
strains that have circulated in Sicily 
for years.
This case represents the third re-
port of meningitis or meningoenceph-
alitis caused by TOSV infection in a 
US traveler to the Mediterranean (all 
acquired in Italy) (7,8). As is shown 
by this and other recent reports of 
TOSV infections in the Mediterranean 
islands surrounding Italy (9), the geo-
graphic range of TOSV human infec-
tions is larger than previously known. 
Reports of TOSV infection among 
European travelers returning from dis-
ease-endemic regions have provided 
additional evidence of the emergence 
of TOSV-related illness on a global 
scale (10).
Although the clinical course var-
ies from asymptomatic infection to 
severe meningoencephalitis, TOSV 
should be included in the differential 
list of viral pathogens among patients 
who seek treatment with symptoms 
consistent with meningitis or encepha-
litis if the patients have recently trav-
eled to Mediterranean areas, includ-
ing Sicily. Because neither a vaccine 
nor specifi c antiviral drug treatment 
is available to prevent or treat TOSV 
infection, travelers to TOSV-endemic 
areas should be advised to take all pre-
cautions to prevent insect bites.
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Figure. Phylogeny of Toscana viruses (TOSVs) of diverse origin. Partial small (S) and 
medium (M) segment sequences of interest were aligned by using ClustalW (www.ebi.
ac.uk/Tools/clustalw2/index.html), and neighbor-joining and maximum-parsimony trees 
were generated by using 2,000 bootstrap replicates with MEGA version 4 (6). Highly similar 
topologies and confi dence values were derived by all methods, and a neighbor-joining tree 
generated from a comparison of 424 nt of the M segment polyprotein gene open reading 
frame is displayed here. GenBank accession numbers appear after the location and source 
of isolation for each taxon. Scale bar represents the number of nucleotide substitutions 
per site. Of interest, the 2009 Sicilian TOSV described in this study (Sicily, human, 2009) 
aggregates with extreme support along with other Italian viruses, including an isolate that 
was derived from sandfl ies in Palermo, Sicily, in 1993.
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Hospital Discharge 
Data for Guillain-
Barré Syndrome 
and Infl uenza A 
(H1N1) Vaccine 
Adverse Events 
To the Editor: As part of the 
public health response to the current 
pandemic (H1N1) 2009, surveillance 
for adverse events following vac-
cination for infl uenza A (H1N1) is 
a high priority (1). Surveillance for 
Guillain-Barré syndrome (GBS) has 
been of particular interest, because 
the syndrome was associated with the 
1976–1977 swine infl uenza vaccine 
(1,2). To study this association, reli-
able ascertainment of recent incident 
cases of GBS is necessary. 
GBS is an acute, immune-me-
diated paralytic disorder of the pe-
ripheral nervous system (3–5) with 
an estimated annual incidence of 
0.8–1.9/100,000 (6). Most cases are 
associated with an antecedent infec-
tion (6). Several surveillance systems 
are in place to monitor rates of post-
vaccination GBS (1–3), most of which 
include a component of electronic 
administrative record review for case 
detection. Analysis of computerized 
medical databases is a well-established 
method of monitoring for vaccine ad-
verse events (7). Although the validity 
of such data varies, depending on the 
diagnosis and region, few studies have 
evaluated the use of hospital discharge 
data for GBS specifi cally (8,9).
We reviewed the Tennessee De-
partment of Health Uniform Hospi-
tal Discharge Dataset for all hospi-
tal discharge diagnoses in 4 major 
metropolitan regions of Tennessee in 
2002–2003 with codes from the In-
ternational Classifi cation of Diseases, 
9th Revision, Clinical Modifi cation 
(ICD-9-CM), that might indicate acute 
GBS. Records with ICD-9-CM code 
357.0 (acute infective polyneuritis) 
or other combinations suggestive of 
GBS within the top 10 diagnoses were 
requested. These data were compared 
with information on cases identifi ed 
by directly requesting lists of patients 
with discharge diagnoses of GBS from 
hospital medical record departments. 
Charts of all reported cases were vali-
dated by chart review. Patients were 
classifi ed as having acute GBS if they 
met Brighton Criteria Levels 1, 2, or 
3 (10).
A total of 344 records of possible 
cases of acute GBS were identifi ed. Of 
these cases, 215 (63%) were identifi ed 
through the state hospital discharge 
database, 315 (92%) were reported 
directly by hospitals, and 186 (54%) 
were identifi ed by both systems. 
Among all suspected cases identifi ed, 
only 103 (30%) met criteria for acute 
GBS (annual rate 2.1/100,000 popu-
lation), 14 (4%) were in out-of-state 
residents, 114 (33%) were nonacute 
cases that occurred before the study 
period and patients were readmitted 
for other reasons, 90 (26%) had no 
documentation of GBS in the medi-
cal record, 17 (5%) were duplicate 
reports, and 6 (2%) had insuffi cient 
information for further investigation. 
The predictive-value positive of a 
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